Literature DB >> 10212752

Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study.

C Betriu1, M C Casado, M Gómez, A Sanchez, M L Palau, J J Picazo.   

Abstract

We studied the evolution of susceptibility of Streptococcus pyogenes isolated in our hospital from 1987 to 1996. Susceptibility to penicillin, ampicillin, cefotaxime, cefuroxime, imipenem, erythromycin, clindamycin, tetracycline, vancomycin, ciprofloxacin, rifampin, and chloramphenicol was determined by the National Committee for Clinical Laboratory Standards broth microdilution method. Differentiation of phenotypes of erythromycin-resistant strains was performed using the double-disc method. All isolates remained very susceptible in vitro to penicillin and all of the other beta-lactam agents tested. Between 1987 and 1995 the incidence of erythromycin resistant strains remained below 5%; the difference in the resistance rate between 1995 (2.6%) and 1996 (17.1%) was statistically significant. The macrolide resistance M phenotype was the most frequent. The isolation rates of tetracycline-resistant strains increased from 2.2% in 1987 to 11.2% in 1988. The marked increase in the incidence of erythromycin resistance observed in our area warrants periodic surveillance of antibiotic susceptibility of S. pyogenes isolates and emphasizes the need to control outpatient antibiotics. The preponderance of the M phenotype may have implications in the choice of antibiotic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212752     DOI: 10.1016/s0732-8893(98)00155-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

1.  Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.

Authors:  C Betriu; M Redondo; M L Palau; A Sánchez; M Gómez; E Culebras; A Boloix; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 2.  The use of macrolides in treatment of upper respiratory tract infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel DeCorby; George G Zhanel
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

3.  The Use of Macrolides in Treatment of Upper Respiratory Tract Infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel Decorby; George G Zhanel
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

4.  The Use of Ketolides in Treatment of Upper Respiratory Tract Infections.

Authors:  George G. Zhanel; Aleksandra K. Wierzbowski; PhD Hisanaga; Daryl J. Hoban
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

5.  Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Chun-Ming Lee; Wen-Kuei Huang; Tsu-Lan Wu; Jen-Hsien Wan; Dine Yang; Jainn-Ming Shyr; Yin-Ching Chuang; Jing-Jou Yan; Jang-Jih Lu; Jiunn-Jong Wu; Wen-Chien Ko; Feng-Yee Chang; Yi-Chueh Yang; Yeu-Jun Lau; Yung-Ching Liu; Hsieh-Shong Leu; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance.

Authors:  C Betriu; E Culebras; I Rodríguez-Avial; M Gómez; B A Sánchez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Ribosomal Resistance: Emerging Problems and Potential Solutions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

8.  [Consensus document on the diagnosis and treatment of acute tonsillopharyngitis].

Authors:  R Piñeiro Pérez; F Hijano Bandera; F Alvez González; A Fernández Landaluce; J C Silva Rico; C Pérez Cánovas; C Calvo Rey; M J Cilleruelo Ortega
Journal:  An Pediatr (Barc)       Date:  2011-09-14       Impact factor: 1.500

Review 9.  [Patient consent to "antimicrobial treatment of tonsillitis"].

Authors:  C Cenjor; J A García-Rodríguez; A Ramos; J Cervera; M Tomás; F Asensi; J L Cañada; M Gobernado; T Isasiá; C López-Madroñero; M Martínez; F Pérez-Escanilla; J Picazo; J Prieto; T Sampelayo
Journal:  Acta Otorrinolaringol Esp       Date:  2003-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.